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demonstrated that 74% of patients with polycythemia vera (PV), 32% of essential thrombocythemia (ET), and 35% of patients with primary MF harbored the JAK2 V617F mutation. Recently, Steensma et al 5 demonstrated that 5% (five of 101 patients) of myelodysplastic syndromes (MDS) patients had the JAK2 V617F tyrosine kinase mutation and reported its infrequent occurrence in other myeloid disorders, including MDS. However, the exact significance of the JAK2 V617F mutation in MDS is obscure. Myelofibrosis is associated with various hematologic diseases as a terminal hematologic condition and is an important issue in managing patients. Less than 10% of myelodysplastic syndromes (MDS) develop MF during their courses and most of them have unfavorable prognoses. 6 The exact biology of MF in MDS patients is still unknown, since some MDS patients show aspects of both MDS and myeloproliferative disorders, 7 and therefore, it is possible that MF could be associated with MDS as one phenotype of myelproliferative disorders.
We therefore searched for the JAK2 V617F mutation in primary and secondary MF in various hematologic diseases using frozen marrow cells or peripheral blood mononuclear cells from patients after obtaining their written informed consent, using the sequence-specific primer-single molecule fluorescence detection assay (SSP-SMFD) (Bannai M, Higuchi K, Akesaka T, Furukawa M, Yamaoka M, Sato K, Tokunaga K. Single-nucleotide-polymorphism gonotyping for whole-genome-amplified samples using automated fluorescence correlation spectroscopy. Annal Biochem 2004; 327: 215-221). We adopted G-T mutation when the incidence of T-substitute reached more than 10%. Furthermore, we also confirmed the JAK2 V617F mutation using a PCR direct-sequencing (Figure 1) .
Of the MF patients associated with acute myeloid leukemia (n ¼ 3), lymphoma (n ¼ 3), and chronic myeloid leukemia (n ¼ 3), none showed the mutation at the time of diagnosis of MF. Approximately 40% of ET (seven of 16 patients) and primary MF (one of four patients) showed the JAK2 V617F mutation, whereas six of eight patients (75%) with PV showed the mutation. Of note is that two of six patients with MDS terminating in MF showed the mutation at the time of MF, while no MDS patient without MF (MDS: n ¼ 38: 20 had refractory anemia (RA), 16 had RA excess blasts (RAEB), and two patients had RAEB in transformation) had the JAK2 V617F mutation ( Figure 1 ). Our study demonstrated that MDS with MF is sometimes associated with the JAK2 V617F mutation, while other underlying diseases developing MF may involve other pathways. Moreover, these findings permit speculation that MDS patients with the JAK2 V617F mutation may be responsible for secondary MF in MDS patients during the process of MDS progression. Another possibility is that the JAK2 V617F mutation We assessed the JAK2 V617F mutation by the sequencespecific primer single-molecule fluorescence detection assay (SSP-SMFD) (Bannai M, Higuchi K, Akesaka T, Furukawa M, Yamaoka M, Sato K, Tokunaga K. Single-nucleotide-polymorphism gonotyping for whole-genome-amplified samples using automated fluorescence correlation spectroscopy. Annal Biochem 2004; 327: 215-221). This technique utilizes primer extension technology combined with fluorescent polarization. In this method, a fluorescent-labeled ddNTP specific for the mutation is incorporated into the primer, which binds immediately upstream from the mutation site, and the difference in fluorescent polarization between incorporated and unincorporated dd NTPs is detected. Percentages (horizontal axis (G) and vertical axis (T)) indicate extension efficacy of the 20 nm primer, and we adopted G-T mutation when the incidence of T-substitute reached X10%. Diamonds indicate patients with deviation of G-T substitute corresponding to the JAK2 V617F mutation (a). Arrows indicate patients with MDS with MF. PCR-direct sequencing of the complementary strand was also performed in order to confirm mutation of the JAK2 V617F tyrosine kinase (NM_004972) in patients with myelodysplastic syndrome with myelofibrosis. The PCR conditions were as follows; preheating at 951C for 10 min, followed by 40 cycles at 951C for 30 s, 641C for 30 s, and 721C for 1 min, and a final extension at 721C for 10 min. Reactions for direct sequencing of the PCR product were performed with BigDye Terminator ver3.1 (Perkin-Elmer Cetus, Fremont, CA, USA). The upper panel shows no mutation of the JAK2 V617F mutation, and the lower panel shows the C-A substitution of the complementary reverse strand, resulting in the JAK2 V617F mutation (G-T substitution in the forward strand). M indicates C-A mutation of the complementary reverse strand (b). may previously exist and its clinical manifestation mimics MDS, that is, myelodysplastic features with cytopenias, but its biologic nature is closely associated with myeloproliferative disorders. Unfortunately, we did not detect its mutation before MF in our MDS/MF patients. Although MDS patients with MF have an unfavorable prognosis, the current study demonstrates the genotypic heterogeneity of such patients. We have previously reported that HL patients with many mast cells in their tumour tissue have a worse prognosis. 2 Mast cells produce functionally active CD30 ligand (CD30L) and the poorer prognosis has been proposed to be caused by a stimulation of HRS by CD30L. 3 Furthermore, we have shown that mast cells, upon stimulation with CD30, release cytokines and chemokines, among which interleukin-8 (IL-8) is known to have angiogenic properties (manuscript in preparation). In other lymphomas, mast cells are proposed to contribute to angiogenesis. 4 In order to increase our understanding of inflammatory cells, their importance in tumour progression and especially angiogenesis in HL, we investigated the possible relation between the number of mast cells and the microvessel count in primary diagnostic HL tissue. We also wanted to further elucidate the prognostic implication of microvessel count in HL.
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Patient samples and clinical data were acquired from the database of the National Health Care Programme for HL in Sweden. A total of 120 patients treated with curative intention, according to the principles of the Health Care Programme 2 in the Uppsala/Ö rebro health care region between 1989 and 1994, were included. The paraffin-embedded tissue samples were from HL involved lymph nodes from the primary diagnosis. The clinical characteristics are presented in Table 1 . Progression free survival (PFS) and HL specific survival (HLS) were analysed. The mean follow-up of living patients was 11 years (range 6-15 years).
The estimation of the number of microvessels immunohistochemically stained for CD31 (Figure 1) , was done by one of the authors using the Chalkley technique. 5 Three to five fields with the highest concentration of vessels (a hot spot) were counted and an average of the highest three countings in every case was used. In all, 20 cases were recounted independently by another author and the counts correlated with an R-value of 0.75, (P ¼ 0.0002). All evaluations were done without knowledge of patient data. The counts varied from 1 to 12 vessels/hot spot. The median was 3 and the 75th percentile was 4.3 vessels/hot spot. Nonbulky disease correlated to high microvessel count (Table 1) and there was a lower proportion of patients with WBC415 in the upper quartile group (data not shown), but there were no other correlations to histology, laboratory parameters, stage, B-symptoms or sex.
In univariate analyses, HL patients with a high microvessel count, cutoff at the 75th percentile (n ¼ 33), have a worse PFS
